Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

DSpace Repository

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Author: Long, G. V.; Tykodi, S. S.; Schneider, J. G.; Garbe, C.; Gravis, G.; Rashford, M.; Agrawal, S.; Grigoryeva, E.; Bello, A.; Roy, A.; Rollin, L.; Zhao, X.
Tübinger Autor(en):
Garbe, Claus
Published in: Annals of Oncology (2018), Bd. 29, H. 11, S. 2208-2213
Verlagsangabe: Oxford Univ Press
Language: English
Full text: http://dx.doi.org/10.1093/annonc/mdy408
ISSN: 1569-8041
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)